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Summary. In a prospective study the statistical character- 
istics of digital rectal examination (DRE), transrectal 
ultrasound (TRUS), and serologic determination f pros- 
tate-specific antigen (PSA) were assessed in 1230 patients 
aged over 40 years. The sensitivity, specificity, and posi- 
tive and negative predictive values were determined to be 
80.3%, 69.7o70, 58.9o70, and 86.7o70, respectively, for DRE; 
76.5o7o, 62.3o70, 52.3°7o, and 83.1%, respectively, for 
TRUS; and 87.9%, 49.6%, 48.5O7o, and 88.3%, respective- 
ly, for PSA (normal level, 4 ng/ml). The data clearly dem- 
onstrate the nonsuitability of each single measure for reli- 
able early detection of prostatic arcinoma. Connection 
of the parameters in all possible combinations under 
various conditions demonstrated the superiority of the 
test "DRE and PSA > 4 ng/ml" over DRE as the "gold 
standard" and all other options. The use of this approach 
as the first-line raster of an algorithm (outlined herein) 
would allow the detection of prostatic malignancy with a 
specificity of 86.5% and a positive predictive value of 
74.0°7o. Supplementing this screen with short-term con- 
trols in cases in which only one parameter is positive 
("DRE or PSA > 4 ng/ml") might enable the detection f 
almost all patients with prostate cancer. TRUS did not 
provide any additional information. 
The principle that early diagnosis of most human 
malignancies enables detection of cancer at a lower and, 
by definition, more curable stage applies as well for pros- 
tate cancer [7]. According to a survey of the American 
College of Surgeons in 1986 [14], transurethral resection 
has been the most common means to establish the diag- 
nosis of prostatic neoplasms. Over the last decade, how- 
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ever, the diagnostic approach to prostate cancer has been 
enriched by the availability of new immunoserologic as
well as imaging modalities for routine clinical use. The 
advances achieved in these fields prompted us in 1987 to 
evaluate these modalities with respect o their capacity 
for detecting prostate cancer either alone or in combina- 
tion and to compare the results with the findings ob- 
tained by digital rectal examination (DRE), which at that 
time was considered the "gold standard". 
Patients and methods 
In an ongoing prospective study, 1230 men over 40 years of age recruit- 
ed from the total-patients cohort at our institution were investigated for 
the potential presence of a prostatic malignancy by clinical, im- 
munochemical, nd sonographic means. 
Prior to digital rectal examination (DRE), determination f the se- 
rum level of prostate-specific antigen (PSA) was performed using ini- 
tially an immunoradiometric assay and later an immunoenzymatic as-
say employing monoclonal antibodies (Hybritech, Inc.). According to 
the recommendation by the manufacturer, the normal reference interval 
was defined as 0 -  3.9 ng/ml. DRE and transrectal sonography of the 
prostate (TRUS) were performed independently b  board-certified urol- 
ogists who had no knowledge of the test results obtained. TRUS was 
performed in real time using the Combison 320-5 KretzTechnik appara- 
tus equipped with a 7.5-MHz bifocal multiplane transducer as reported 
previously [i]. Sonographic analysis included irregularities of any kind 
with respect to the symmetry, size, and contour of the gland and seminal 
vesicles as well as the margins and the choic pattern of a detected fo- 
cus. The echotexture was defined as echopenic, hypoechoic, 
hyperechoic, or mixed, according to the sonographic phenotype, and 
was interpreted by the criteria reported before the onset of the study for 
differentiation between benign and malignant findings, with special re- 
spect o hyper- and hypoechoic foci [6, 13]. In equivocal cases of DRE, 
a transrectal biopsy using a Tru-Cut needle (Travenol) was performed. 
Statistical evaluation (by B.S.) included a subgroup of only 376 pa- 
tients in whom the accuracy of the diagnosis was assured by histology 
as a comparable r ference test, with proven untreated malignancy being 
determined in 132 cases and proven benign prostatic hyperplasia (BPH), 
in 244 cases. Staging in cases of prostate cancer was performed accord- 
ing to the TNM classification [8]. 
In a multiparameter approach, interpretation of differing results 
poses a problem, since it is unclear which criterion finally has the edge 
in reaching aconclusive diagnosis. Combination of the results obtained 
by the modalities employed is possible in either an "and" or an "or" 
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connection. For unequivocal judgement of the test combinations cho- 
sen in the study, the criteria for selection were defined as follows: 
i. The combined test result of two modalities in the "or" connection 
is considered to be negative if both results are negative with respect 
to malignant transformation. It is interpreted as being positive if one 
or both results are positive. 
2. The combined test result of two modalities in the "and" connection 
is considered to be negative if one or both results are negative. It is 
defined as being positive if both results are positive. 
3. The combined test result of three modalities in the "or" connection 
is considered to be negative if all tests are negative. It is interpreted 
as being positive if at least one of three tests is positive. 
4. The combined test result of three modalities in the "and" connection 
is considered to be negative if at least one of three tests is negative. 
It is interpreted as being positive if all three tests are positive. 
The positive and negative predictive values, respectively, are defined 
correspondingly. 
Results 
Figure 1 illustrates the age distribution of the cancer pa- 
tients, showing one peak in the seventh decade and an- 
other in the eighth decade. Remarkable is the finding that 
as many as one-fifth of the tumor patients were younger 
than 60 years of age. 
Single-modality approach 
Table 1 demonstrates the diagnostic haracteristics of the 
modalities employed in the assessment of the different 
entities. To allow a comparison of the present results with 
initial reports on PSA in the early 1980s, the normal ref- 
erence interval of 0-2.7 ng/ml recommended at those 
times is listed additionally. Statistical analysis of the 
mean PSA values obtained in the tumorous and non- 
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Fig. 1, Distribution of patients' age. • Total cohort (376); [] non-can- 
cer (244); [] cancer (132) 
cancerous patients revealed a highly significant difference 
between the two cohorts (P< 0.005). 
Two-modality approach 
Using two modalities and connecting the results in an 
"or" fashion increases the sensitivity of this approach, 
but a remarkable loss of specificity simultaneously ob- 
tained as compared with the characteristics of the modal- 
ities used as single measures (Table 2). A positive test re- 
sult would not justify subsequent invasive diagnostic 
measures since almost half of the healthy patients would 
undergo biopsy unnecessarily. However, the combination 
"DRE or PSA > 4 ng/ml" has to be emphasized because 
it proved to be superior in sensitivity by 13.7% as com- 
pared with the combination "DRE or TRUS" 
Table 1. Efficacy of the single modalities in 132 patients with pCa and 244 patients with BPH 
Method PCA- BPH- Sensitivity Specificity Positive pred. Negative pred. 
positive negative (070) (070) value (070) value (%) 
DRE 106 170 80.3 69.7 58.9 86.7 
TRUS 101 152 76.5 62.3 52.3 83.1 
PSA (2.7) 123 94 93.2 38.5 45.1 91.3 
PSA (4.0) 116 121 87.9 49.6 48.5 88.3 
PSA (10.0) 84 186 63.6 76.2 59.2 79.5 
PSA values are expressed in ng/ml,  pCa, Prostate cancer; pred. value, predictive value 
Table 2. Efficacy of two modalities as determined using an "or" combination, i e., only one of the two being indicative of pCa, in 132 patients 
with pCa and 244 patients with BPH 
Method PCA- BPH- Sensitivity Specificity Positive pred. Negative pred. 
positive negative (%) (%) value (070) value (%) 
DRE or TRUS 110 138 83.3 56.6 50.9 86.3 
DRE or PSA (2.7) 130 60 98.5 24.6 41.4 96.8 
DRE or PSA (4.0) 128 80 97.0 32.8 43.8 95.2 
DRE or PSA (10.0) 123 124 93.2 50.8 50.6 93.2 
TRUS or PSA (2.7) 130 54 98.5 22.1 40.6 96.4 
TRUS or PSA (4.0) 128 72 97.0 29.5 42.7 94.7 
TRUS or PSA (10.0) 123 114 93.2 46.7 48.6 92.7 
PSA values are expressed in ng/ml, pCa, Prostate cancer; pred. value, predictive value 
Connecting the test results of two modalities in an 
"and" fashion slightly decreases the sensitivity as com- 
pared with the characteristics of the single modalities, but 
a remarkable increase in specificity is achieved (Table 3). 
The optimal balance between sensitivity and specificity is 
accomplished with the combination "DRE and 
PSA > 4 ng/ml"; malignant transformation is assessed in 
71.2% of cases with a specificity of 86.5O7o. The combina- 
tion of "DRE and PSA> 10 ng/ml" would allow a fur- 
ther increase in specificity; however, almost one-fifth of 
all prostate cancers remain undetected as shown by the 
corresponding sensitivity loss of 20.4%. The combination 
of "DRE and PSA>4ng/ml"  is also superior as com- 
pared with "TRUS and PSA > 4 ng/ml" in terms of sensi- 
tivity and specificity. The approach "DRE and TRUS" as 
compared with "DRE and PSA > 4 ng/ml" allows a mini- 
mal increase of 2.3% in sensitivity but carries a specifici- 
ty loss of l 1.1%. The test combinations in couples dem- 
onstrate that TRUS does not provide an additional bene- 
fit to DRE or PSA determination. 
Three-modafity approach 
The three-modality approach does not confirm our initial 
expectations [1] (Table4). Excluding the combinations 
with PSA > 2.7 ng/ml, since 4 ng/ml is now the standard 
normal value, the combination of "DRE and TRUS and 
PSA > 4 ng/ml" with its specificity of 90.2°7o seems to be 
the best. However, the gain in specificity as compared 
with "DRE and PSA > 4 ng/ml" simultaneously carries a 
greater sensitivity loss of 6.8070. Applying "DRE or 
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TRUS or PSA > 4 ng/ml" results in the same sensitivity 
achieved with "DRE or PSA > 4 ng/ml" but is associated 
with a loss of 5.3 % in specificity. The optimal specificity 
of 96.3% is achieved by "DRE and TRUS and 
PSA> 10 ng/ml;' but only at the cost of a failure to de- 
tect more than half of all cancer patients. Also in the tri- 
ple approach, TRUS does not provide additional infor- 
mation. 
Algorithm 
Considering the obvious lack of additional information 
associated with using the diagnostic measures in a triple 
combination as well as the limited specificity of the single 
modalities, two approaches deserve closer attention: 
"DRE or PSA>4 ng/ml" and "DRE and PSA>4 ng/ 
ml." Although the first is marked by a high sensitivity of 
97%, the latter exhibits an outstanding specificity of 
86.5%, which makes the application of fine needle biopsy 
reasonable to prove the malignancy histologically in 
71.2% of the patients. 
The difference in sensitivity of 25.8°7o between this 
combination and the value of 9707o provided by "DRE or 
PSA > 4 ng/ml" is created by the subgroup of patients in 
whom only one marker is indicative of malignancy. Thus, 
the combination "DRE and PSA>4ng/ml"  does not 
seem to be suitable for use as a single screen due to its 
sensitivity of only 71.2%. Therefore, an additional raster 
utilizing the indicative potential of the combination 
"DRE or PSA> 4 ng/ml~' which allows a detection rate 
of 97%, appears uitable. Since the specificity of the lat- 
Table 3. Efficacy of two modalities as determined using an "and" combination, i.e., both being suggestive for pCa, in 132 patients with pCa and 
244 patients with BPH 
Method PCA- BPH- Sensitivity Specificity Positive pred. Negative pred. 
positive negative (%) (%) value (%) value (%) 
DRE and TRUS 97 184 73.5 75.4 61.8 84.0 
DRE and PSA (2.7) 99 204 75.0 83.6 71.2 86.1 
DRE and PSA (4.0) 94 211 71.2 86.5 74.0 84.7 
DRE and PSA (10.0) 67 232 50.8 95.1 84.8 78.i 
TRUS and PSA (2.7) 94 I92 71.2 78.7 64.4 83.5 
TRUS and PSA (4.0) 89 201 67.4 82.4 67.4 82.4 
TRUS and PSA (10.0) 62 224 47.0 91.8 75.6 76.2 
PSA values are expressed in ng/ml, pCa, Prostate cancer; pred. value, predictive value 
Table 4. Efficacy of three modalities as determined using an "or" and "and" combination, i.e., one of the three or all three being suggestive for 
pCa, in i32 patients with pCa and 244 patients with BPH 
Method PCA- BPH- Sensitivity Specificity Positive pred. Negative pred. 
positive negative (%) (%) value (%) value (%) 
DRE or TRUS or PSA (2.7) 130 49 
DRE or TRUS or PSA (4.0) 128 67 
DRE or TRUS or PSA (10.0) 124 103 
DRE and TRUS 'and PSA (2.7) 90 213 
DRE and TRUS and PSA (4.0) 85 220 
DRE and TRUS and PSA (10.0) 59 235 
98.5 20.1 40.0 96.1 
97.0 27.5 42.0 94.4 
93.9 42.2 46.8 92.8 
68.2 87.3 74.4 83.5 
64.4 90.2 78.0 82.4 
44.7 96.3 86.8 76.3 
PSA values are expressed in ng/ml, pCa, Prostate cancer; pred. value, predictive value 
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Table 5. Suggested algorithm for the early detection of prostate cancer 
DRE + and PSA > 4 ng/ml  --, biopsy 
DRE + or PSA > 4 ng/ml--* 3-monthly control 
DRE-  and PSA > 4 ng/ml--,  yearly preventive check-up 
ter combination (32.8%) would not justify invasive diag- 
nostic procedures, in this group of patients with only one 
parameter suspicious for prostate cancer, a short-term 
control appears more appropriate (Table 5). 
In this context, it is emphasized that the percentage of
change in PSA levels per year was found to be significant- 
ly greater in men with prostate cancer as compared with 
men with BPH (P< 0,03). These data suggest hat serial 
determinations of PSA levels may be useful in detecting 
prostate cancer earlier [2]. 
If both parameters are negative, e.g., the DRE is nor- 
mal and PSA levels are < 4 ng/ml, there is a probability 
of 95.2% that the patient will not suffer from prostate 
cancer. In these low-risk cases, check-ups at longer inter- 
vals seem to be acceptable. 
The use of such an approach according to the cor- 
responding probability of selection would allow the de- 
tection of 71.2% of all prostate cancer patients and 
would provide the histologic proof as early as at their 
first presentation. In addition, 25.8% of the tumorous 
patients could be detected by subsequent short-term con- 
trols. Only 3% of tumorous cases are not diagnosed by 
this strategy (Table6). Whereas 32.8% of the non 
cancerous patients are correctly diagnosed, 13.5% would 
undergo biopsy and 53.7% would be subjected to further 
control check-ups unnecessarily. However, the latter 
seems tolerable, since DRE and blood tests are nonin- 
vasive diagnostic measures. 
Discussion 
The study of the American College of Surgeons [14] re- 
ports 5-year survival values for patients with prostate 
cancer according to the clinical stages A, B, C, and D of 
85%, 77%, 65.5%, and 30%, respectively. Paulson et al. 
[11] found a 5-year survival value of 90% for patients 
with stages T lb and T2 disease after radical prostatec- 
tomy, Approximately 85% of patients with lymphatic 
spread of prostatic arcinoma develop distant metastases 
Table 6. Probabilility of selection in checking a population for prostate 
cancer according to the algorithm 
pCa Patients: 
True positive ~ histologic confirmation 
Control ~ postponed etection 
False negative --, loss 
Total 
Non-pCa patients: 
False positive -* biopsy unnecessary 
control unnecessary 
True negative 
Total 
71.2070 
25.8% 
3.0% 
100.0% 
13.5070 
53.7% 
32.8% 
100.0% 
within 5 years, and the vast majority of these die within 
3 years thereafter. Of patients with stage D2 disease, 
about 50% die of prostate cancer within 30 months, 80% 
die within 5 years, and 90% succumb within 10 years [3]. 
These data underscore the possibility of a cure in cases of 
a diagnosis at an early stage, when the disease is confined 
to the gland, and simultaneously define the requirements 
for an adequate diagnostic approach. 
Using DRE as the "gold standard~' 32% of carcino- 
mas will be missed, even by experienced examiners [9]. 
Thompson et al. [15] presented the results of routine 
urologic screening of 2005 men between 40 and 70 years 
old and found DRE to be an insensitive screening device 
with poor predictive value. As reasons for the insensitivi- 
ty, the authors discussed the localization of the tumor as 
well as the missing palpable abnormality and suggested 
as early as in •984 the use of adjunctive tools for the de- 
tection of adenocarcinoma of the prostate [15]. In our 
study we obtained similar results. Exclusive performance 
of DRE had not detected 20% of cancers; in addition, the 
specificity of the test with only 69.7% due to a variety of 
benign reasons for induration cannot be considered ade- 
quate. 
The sensitivity of TRUS (76.5%) proved to be inferior 
as compared with DRE, as did its specificity and disap- 
pointing positive predictive value of 52.3%. Even though 
we used the most advanced technology by employing a
7.5-MHz multifocal multiplane transducer, we obtained 
an improvement of only 20% in the results reported by 
Chodak et al. [5]. 
Statistical analysis of the PSA data at first confirmed 
this glycoprotein to be a tumor marker due to the highly 
significant difference between cancerous and noncancer- 
ous patients. Furthermore, our results ubstantiate he ex- 
tension of the normal reference interval from 0-2.7 ng/ 
ml in the early 1980s to the currently worldwide accepted 
range of 0 -  3.9 ng/ml as recommended by the manufac- 
turer. The actual normal range demonstrates a loss of 
5.3% in sensitivity; however, the specificity is simulta- 
neously increased by 11.1%. A further extension up to 
9,9 ng/ml proved to be inappropriate in discriminating 
these entities, because 24.3% of the cancer patients in our 
study would not have been detected. 
In our cancer patients PSA levels were found to be 
above the normal range in 87.9°70 of cases, but this also 
applied to 50.407o f the BPH patients. Due to its organ- 
specific but not umor-specific character, PSA is not suit- 
able as a single measure for early detection of prostate 
cancer as demonstrated by its specificity of 49.6%. 
It is noteworthy that the sensitivity, specificity, and 
predictive value requirements of a test differ in different 
settings [12]. In an early detection program the specificity 
has to be reasonably high. Even though the patients in- 
vestigated represent a selected group since they were re- 
cruited in the setting of a urology department, the state- 
ments regarding the quality of the single measures for the 
detection of prostate cancer are not affected adversely. 
Considering the specificity of the single tests, it becomes 
obvious that none meets the requirements for an early de- 
tection program. Combining DRE with TRUS in an "or" 
fashion achieves an increase of only 2% in sensitivity as 
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compared with DRE alone. In contrast, the combination 
of DRE and PSA > 4 ng/ml in an "or" fashion provides 
a sensitivity increase of 16.7°70. However, this screen is 
hampered by its low specificity of 32.8% and is not ap- 
propriate as a single measure for an early detection pro- 
gram. As an improved first raster, the combination "DRE 
and PSA>4ng/ml"  recommends itself, meeting the 
outlined conditions regarding specificity while simulta- 
neously exhibiting an acceptable sensitivity. 
When all possible combinations of the modalities in 
"or" and "and" connections are considered, the variabili- 
ty of prostate cancer with respect to its clinical, im- 
munoserologic, and sonographic phenotype becomes ap- 
parent. This heterogeneity is furthermore reflected by the 
observation that in the search for an optimal approach 
for early detection, a gain of specificity is accompanied 
by a loss of sensitivity, and vice versa. Our data confirm 
the results of Catalona et al. [4] that the combination of 
the serum PSA concentration and DRE increases the rate 
of detection of prostate cancer. However, we could not 
prove that any additional information was provided by 
TRUS. Using palpation and TRUS (7.0MHz axial, 
5.0 MHz sagittal) in a study of 315 asymptomatic men, 
Palken et al. [I0] also found both methods equieffective 
and recommended the clinical investigation with respect 
to costs. 
Our work exclusively demonstrates the superiority of  
a combined approach over the "gold standard" in the ear- 
ly detection of  prostate cancer. By no means does this 
study provide information about the value of  an early de- 
tection program with regard to the morbidity and mortal- 
ity of  prostate cancer. This question can be answered only 
by a prospective multicenter randomized study that is 
based on the algorithm outl ined herein and includes 
treatment modalit ies and patient care as well. Meanwhile, 
opportunit ies to detect prostate cancer early should not 
be missed by the urologic communi ty  employing the 
knowledge gained thus far about the characteristics of  
various diagnostic measures. 
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